Literature DB >> 9517757

Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study.

M J Plant1, P W Jones, J Saklatvala, W E Ollier, P T Dawes.   

Abstract

OBJECTIVE: To describe the course of radiological progression in a cohort of 126 patients presenting with early nonerosive rheumatoid arthritis (RA).
METHODS: Criteria for recruitment to the study were fulfillment of the 1958 American Rheumatism Association criteria, absence of erosive disease at presentation and duration of symptoms less than 3 years. Radiographs of hands and feet at 0, 1, 2, 5, and 8 years were available on 114 patients and were scored by Sharp's method for erosion (ERO) and joint space narrowing (JSN). Eighty-six patients were typed for the RA susceptibility shared HLA-DR epitope.
RESULTS: The feet showed greatest initial radiological progression, but tended to reach an earlier and lower plateau. ERO progressed more rapidly than JSN in the first 2 years, but in parallel thereafter. The relative proportion of ERO:JSN varied, 1:1 for the wrists, 4:1 for the proximal interphalangeal joints. Thirty-eight percent of joints were eroded at 2 years, 63% at 8 years. Four patterns of radiological progression were identified: flat or nonerosive disease in 29 patients, linear in 51, lag in 13, and plateau in 19 (irregular in 2). Changes in the rate of radiological progression were reflected by the time-integrated C-reactive protein over the same period. Rheumatoid factor titer was higher in the progressive groups compared to the flat group (p = 0.01). The RA susceptibility shared HLA-DR epitope was more frequent in the linear compared to the flat group (p = 0.03).
CONCLUSION: A large proportion of joints become eroded in the first 2 years of early RA. The subsequent course of radiological progression is highly variable and cannot be easily explained by any single model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517757

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

1.  Ultrasonography in the evaluation of bone erosions.

Authors:  W Grassi; E Filippucci; A Farina; F Salaffi; C Cervini
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 2.  Interpreting radiographic data in rheumatoid arthritis.

Authors:  P A Ory
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

3.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

4.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

5.  Dynamic exercises in patients with rheumatoid arthritis.

Authors:  A P Anandarajah; E M Schwarz
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 6.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 7.  An overview of commonly used radiographic scoring methods in rheumatoid arthritis clinical trials.

Authors:  Vinod Ravindran; Satish Rachapalli
Journal:  Clin Rheumatol       Date:  2010-08-21       Impact factor: 2.980

8.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 9.  Presentation and analysis of radiographic data in clinical trials and observational studies.

Authors:  R Landewé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 10.  Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis.

Authors:  Vincent van Drongelen; Joseph Holoshitz
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.